Only Covaxin Gives 65.2% Efficacy Against COVID-19 Delta Variant: Lancet

The recent study by the Lancet peer-review said Covaxin surpassed all the vaccines in terms of efficacy against the Delta variant by providing 65.2% efficacy, said vaccine maker Bharat Biotech on November 12. The Lancet also said that it provides 77.8% efficiency against symptomatic patients. It provides ''70.8% protection against all variants of SARS-CoV-2 virus,'' said the maker. However, 12% of people experienced common side effects of the vaccine.